**Research Article: Pregnancy**

**Gestational diabetes and adiposity are independent risk factors for perinatal outcomes: a population based cohort study in Sweden**

K. Hildén, U. Hanson, M. Persson, A. Magnuson, D. Simmons and H. Fadl

1Department of Obstetrics & Gynaecology, School of Medical Sciences, Örebro University, 2School of Medical Sciences, Örebro University, Örebro, 3Department of Women’s and Children’s Health, Uppsala University, Uppsala, 4Department of Medicine, Clinical Epidemiology Unit, Karolinska Universitetssjukhuset, Solna, 5Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden and 6School of Medicine, Western Sydney University, Campbelltown, NSW, Australia

Accepted 18 October 2018

**Abstract**

**Aims** To evaluate the interaction effects of gestational diabetes (GDM) with obesity on perinatal outcomes.

**Methods** A population-based cohort study in Sweden excluding women without pre-gestational diabetes with a singleton birth between 1998 and 2012. Logistic regression was performed to evaluate the potential independent associations of GDM and BMI with adverse perinatal outcomes as well as their interactions. Main outcome measures were malformations, stillbirths, perinatal mortality, low Apgar score, fetal distress, prematurity and Erb’s palsy.

**Results** Some 1,294,006 women were included, with a GDM prevalence of 1% (n = 14,833). The rate of overweight/obesity was 67.7% in the GDM-group and 36.1% in the non-GDM-group. No significant interaction existed. Offspring of women with GDM had significantly increased risk of malformations, adjusted odds ratio (aOR) 1.16 (95% confidence intervals 1.06–1.26), prematurity, aOR 1.86 (1.76–1.98), low Apgar score, aOR 1.36 (1.10–1.70), fetal distress, aOR 1.09 (1.02–1.16) and Erb’s palsy aOR 2.26 (1.79–2.86). No risk for stillbirth or perinatal mortality was seen. Offspring of overweight (BMI 25–29.9 kg/m²), obese (BMI 30–34.9 kg/m²) and severely obese women (BMI ≥ 35.0 kg/m²) had significantly increased risks of all outcomes including stillbirth 1.51 (1.40–1.62) to 2.85 (2.52–3.22) and perinatal mortality 1.49 (1.40–1.59) to 2.83 (2.54–3.15).

**Conclusions** There is no interaction effect between GDM and BMI for the studied outcomes. Higher BMI and GDM are major independent risk factors for most serious adverse perinatal outcomes. More effective pre-pregnancy and antenatal interventions are required to prevent serious adverse pregnancy outcomes among women with either GDM or high BMI.

Diabet. Med. 36, 151–157 (2019)

**Introduction**

Overweight and obesity are public health problems in many parts of the world. In 2014, 39% of the world’s population was overweight and 13% were obese [1]. The high prevalence of obesity among women of childbearing age is unprecedented [2]. The incidence of gestational diabetes mellitus (GDM) in Sweden has increased slowly as a consequence of increased rates of obesity, immigration and higher maternal age [3]. It is well known that both GDM and overweight/obesity increase risks for maternal and fetal complications in pregnancy, delivery and the neonatal period [4–10]. Whether adverse outcomes are related to GDM (hyperglycaemia) per se or to overweight/obesity (50–70% of women with GDM are overweight/obese) is known to some extent [11,12]. We have previously demonstrated that normal weight women with GDM have the same increments in risk for adverse maternal outcomes and excessive fetal growth as overweight women without GDM [13]. However, data on serious perinatal outcomes remain scant, and conflicting information on risks of malformations and perinatal mortality in offspring of women with GDM have been presented [14,15].

Visceral fat increases insulin resistance and potentiates development of the metabolic syndrome. This suggests that
the combination of overweight and GDM could amplify the risk of adverse perinatal outcomes creating a multiplicative or additive effect [16]. Such information would be helpful in the clinical setting to identify pregnancies at higher risk of complications.

Our first aim was to evaluate possible interaction effects between maternal BMI and GDM on adverse perinatal outcomes. Second, we evaluated whether, and how, maternal excess weight (overweight, obesity, severe obesity) and GDM are independently associated with adverse perinatal outcomes.

**Participants and methods**

The study population consisted of all women with a singleton birth in Sweden between 1998 and 2012. Data were derived from the Medical Birth Register (MBR) which is maintained by the National Board of Health and Welfare. The register contains data on ≥ 98% of births in Sweden since 1973 [17]. Information on all hospital births is collected prospectively and includes demographic data and diagnoses during pregnancy, delivery and the neonatal period, using standardized forms. The MBR is validated regularly and the quality of the variables included in the present investigation is high [17]. Women with pre-gestational diabetes (Type 1 and Type 2 diabetes mellitus) were excluded from this analysis. Records with extreme values for height and weight were excluded (weight < 35 kg or > 200 kg and height < 140 cm or > 200 cm). Maternal BMI was calculated as weight in kilograms divided by height in metres squared. BMI categories were defined according to the WHO classification as underweight (BMI < 18.5 kg/m²), normal weight (18.5–24.9 kg/m²) overweight (25.0–29.9 kg/m²), obese (30.0–34.9 kg/m²) and severely obese (≥ 35 kg/m²). Weight was measured at the first visit to maternity care, usually taking place in the first trimester [18]. Height was reported by recall.

In Sweden, the main screening strategy for GDM during the study period was based on repeated, random, capillary blood glucose ≥ 8 mmol/l (plasma glucose ≥ 9.0 mmol/l) and/or traditional risk factors, i.e. first-degree family history of diabetes, previous delivery of large for gestational age babies, GDM in an earlier pregnancy. Some regions also included obesity as a risk factor. Diagnosis of GDM was based on the 75-g oral glucose tolerance test (OGTT). If elevated random, capillary blood glucose (> 9 mmol/l) was detected in the first trimester, an OGTT was performed with a repeat test during the second trimester. Otherwise the OGTT was performed in gestational week 28–32. During 1998–2012, there was a shift towards performing the OGTT in gestational week 24–28 which is in line with international guidelines. The Swedish MBR does not have the timing of OGTT documented. During the study period, the main diagnostic criteria for GDM were fasting, capillary, whole-blood glucose ≥ 6 mmol/l and/or 2-h blood glucose ≥ 9 mmol/l. In the middle of the study period, there was a switch from measuring whole-blood glucose to plasma glucose. The diagnostic criteria based on plasma glucose included cut-off levels for fasting glucose of ≥ 7.0 mmol/l and for 2-h glucose of ≥ 10.0 mmol/l. A small region in Sweden has offered a simplified 75-g OGTT (including only the 2-h blood glucose measurement) to all pregnant women since 1995. The diagnostic criteria for GDM for this simplified OGTT was 2-h blood glucose ≥ 10.0 mmol/l [19]. In another region, during 1998–2010, only women with values corresponding to overt diabetes (fasting capillary plasma glucose ≥ 7 mmol/l or 2-h plasma glucose ≥ 12.2 mmol/l) were diagnosed with GDM. This region represents ~ 20–25% of the pregnant population.

The register does not contain data on laboratory measures such as blood glucose. GDM and neonatal outcomes were identified based on International Classification of Diseases version 10 (ICD-10) codes. GDM was identified as ICD code O24.4A or O24.4B. Chronic hypertensive disease (CHD) was defined as hypertension diagnosed before pregnancy or blood pressure ≥ 140/90 mmHg before week 20 of gestation (O10.0, O10.2, O10.4 and O10.9). Preterm delivery was defined as birth before 37 completed weeks of gestation. Malformations include all ICD codes Q00–Q99. The definition of stillbirth changed during the study period. Before 2008, stillbirth was defined as birth of a dead fetus after 28 completed gestational weeks. From 2008, stillbirth was defined in the MBR as fetal death after 22 completed gestational weeks (ICD code O36.4). Perinatal mortality included both stillbirths and deaths during the first 7 days postpartum. Fetal distress was defined as a reason for intervention (i.e. Caesarean section or vacuum extraction) due to suspected fetal hypoxia during pregnancy or delivery (ICD code O68.9). Low Apgar score was defined as Apgar < 4 points at 5 min of age. Erb’s palsy was identified based on ICD code P14.0. Sensitivity analysis was done to account for possible differences between regions and the effects of overt diabetes during pregnancy.
The study was approved by the Regional Ethical Committee in Uppsala, Sweden (2009/187/1).

Statistical analyses

To compare maternal characteristics and perinatal outcomes between women with and without GDM the \( \chi^2 \) test was used, except for maternal age and BMI for which the unpaired \( t \)-test was used. To compare maternal characteristics and perinatal outcomes between BMI groups the \( \chi^2 \) test for trend was used for all variables, except maternal age for which analysis of covariance was used as a trend test. Unadjusted, logistic regression was used to compare perinatal outcomes in offspring in relation to mothers’ GDM and BMI separately. Adjustment was made for GDM and BMI by having the variables in the same model and further adjustment was made for other potential confounders such as maternal age, non-Nordic decent, parity, smoking and chronic hypertension. Finally, in the final adjusted model, an interaction test of GDM and BMI was assessed which evaluates whether GDM potentiates rather than simply adds to the effect of obesity on the risk of adverse outcomes. In the logistic regression models, all independent variables were entered as categorical except for maternal age which was evaluated on a continuous scale. Logistic regression gave odds ratios (OR) with 95% confidence intervals (95% CI) as measure of association. A \( P \)-value < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS statistical software, version 22 (IBM, Armonk, NY, USA).

Results

After exclusion of women with Type 1 and Type 2 diabetes before pregnancy, and women with multiple pregnancies, the study cohort included 1,294,006 women with data on early pregnancy BMI; 14,833 women (1%) were diagnosed with GDM. Data on BMI were missing in 11% of the women; however, the proportion of GDM in women without information on BMI was the same (1%) as in women with BMI data. For detailed characteristics of women with missing data on BMI see Table S1. Of all studied women, 35.9% had a BMI \( \geq 25 \) kg/m\(^2\) and 11.3% had a BMI \( \geq 30 \) kg/m\(^2\). Among women with GDM, 67.7% were overweight or obese and 37.6% were obese. During the study period, the proportion of women with GDM increased from 0.7% in 1998 to 1.2% in 2012. The proportion of non-Nordic women also increased from 15.7% in 1998 to 24.6% in 2012. Maternal characteristics differed between women with and without GDM (Table 1), and between BMI groups (Table 2).

The proportion of perinatal outcomes in women with and without GDM are presented in Table 1. There were significantly elevated risks of malformations, fetal distress, low Apgar score, prematurity and Erb’s palsy in offspring of women with GDM compared with offspring of women without GDM in the unadjusted model (Table 3). The elevated risks were present after adjusting for BMI and also in the third model with adjustment for other potential confounders (Table 3). There was no increased risk of stillbirth or perinatal mortality in the offspring of women with GDM compared with women without GDM after taking potential confounders into account, including BMI (Table 3). The proportion of perinatal outcomes in women in the different BMI categories are presented in Table 2. Elevated risks of all outcomes were significantly increased in offspring of women that were overweight, obese and severely obese compared with normal weight both unadjusted and adjusted for all potential confounders (Table 3). Risks increased with increasing BMI. The risk increase due to BMI was most pronounced when analysing perinatal death, stillbirth and Erb’s palsy, especially for women with a BMI \( > 30 \) kg/m\(^2\). Including only pregnancies beyond 37 weeks (i.e. term pregnancies) did not alter the results (data not shown). In the adjusted model there was no significant interaction between GDM and BMI for any of the studied outcomes (Table 3).

Sensitivity analysis excluding the region in Sweden diagnosing GDM on values corresponding to overt diabetes did not change the results for any studied outcome (data not shown). All analyses were repeated with BMI on a continuous scale and this also did not change the results.

Discussion

In this large, population-based cohort study in Sweden, we show that, besides for prematurity, the impact of maternal,
excess weight on adverse perinatal outcomes did not differ significantly between the offspring of mothers with and without GDM. Maternal overweight and obesity and GDM are major, independent risk factors for most adverse perinatal outcomes. Offspring of women with GDM had increased risk of malformations, prematurity, fetal distress and Erb’s palsy, but the risks of stillbirth and perinatal mortality were comparable with the risks in the reference population. This was despite being diagnosed with higher glycaemic thresholds than the current WHO criteria [20]. Overweight, obesity and severe obesity were independent risk factors for malformations, stillbirths, perinatal mortality, low Apgar score at 5 min and Erb’s palsy, but the risks of stillbirth and perinatal mortality were independent of GDM. The same independent factors of malformations, but the absolute risk increase was small. Feig et al. [24] also found increased risk of congenital malformations among offspring of women with GDM, but wondered if this was due to overweight and obesity.

Obese women have an increased risk for both stillbirth and perinatal mortality [25,26]. In this study, we found no significant independent effect of GDM after adjusting for potential confounding factors including BMI. There are few large studies with data on rates of perinatal mortality and

Table 2 Maternal characteristics and perinatal outcomes according to BMI

| BMI (kg/m²) | < 18.5 (n = 31 041) | 18.5–24.9 (n = 794 342) | 25–29.9 (n = 322 391) | 30–34.9 (n = 103 942) | > 34.9 (n = 42 290) | P-value* |
|------------|---------------------|------------------------|----------------------|----------------------|---------------------|---------|
| Maternal characteristics | | | | | | |
| GDM | 151 (0.5) | 4114 (0.5) | 3972 (1.2) | 2786 (2.7) | 2185 (5.2) | < 0.01 |
| Age (years) | 27.7 ± 5.3 | 29.9 ± 5.1 | 30.4 ± 5.2 | 30.3 ± 5.4 | 30.2 ± 5.3 | < 0.01 |
| Non-Nordic | 9202 (29.6) | 141 082 (17.8) | 66 944 (29.8) | 21 756 (20.9) | 7114 (16.8) | < 0.01 |
| Primiparous | 16 798 (54.1) | 375 798 (47.3) | 128 140 (39.7) | 37 671 (36.2) | 15 033 (33.5) | < 0.01 |
| Chronic hypertension | 33 (0.1) | 1310 (0.2) | 422 (0.4) | 153 (0.2) | 550 (1.3) | < 0.01 |
| Smoking | 3606 (11.6) | 57 754 (7.3) | 29 223 (9.1) | 12 249 (11.8) | 5838 (13.8) | < 0.01 |
| Perinatal outcomes | | | | | | |
| Malformation | 1055 (3.4) | 27 110 (3.4) | 11 281 (3.5) | 3752 (3.6) | 1633 (3.9) | < 0.01 |
| Perinatal mortality | 91 (0.3) | 2598 (0.3) | 1591 (0.5) | 691 (0.7) | 394 (0.9) | < 0.01 |
| Stillbirth | 69 (0.2) | 1945 (0.2) | 1208 (0.4) | 534 (0.5) | 298 (0.7) | < 0.01 |
| Prematurity | 1916 (6.2) | 35 542 (4.5) | 15 368 (4.8) | 5700 (5.3) | 2843 (6.7) | < 0.01 |
| Appar < 4 at 5 min | 66 (0.2) | 2124 (0.3) | 1242 (0.4) | 495 (0.5) | 315 (0.7) | < 0.01 |
| Fetal distress | 2003 (6.5) | 52 853 (6.7) | 22 516 (7.0) | 7804 (7.5) | 3395 (8.0) | < 0.01 |
| Erb’s palsy | 20 (0.1) | 1025 (0.1) | 727 (0.2) | 343 (0.3) | 191 (0.5) | < 0.01 |

Data are presented as n (%) or mean ± SD.
* Trend test of covariance was used to analyse age. A χ²-test for trend was used for all other maternal characteristics and outcomes. Missing data for BMI was 11%.
Table 3 Gestational diabetes (GDM) and BMI associations on perinatal outcomes analysed with logistic regression

|                      | Unadjusted OR (95% CI) | Adjusted for GDM/BMI* OR (95% CI) | Adjusted for all possible confounders$^7$ OR (95% CI) | P-value |
|----------------------|------------------------|-----------------------------------|------------------------------------------------------|---------|
| **Malformations**    |                        |                                   |                                                      |         |
| GDM                  | 1.20 (1.10–1.30)       | 1.15 (1.06–1.26)                  | 1.16 (1.06–1.26)                                     |         |
| No GDM               | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| BMI groups (kg/m²)   |                        |                                   |                                                      |         |
| < 18.5               | 1.00 (0.94–1.06)       | 1.0 (0.94–1.06)                   | 1.02 (0.95–1.08)                                     |         |
| 18.5–24.9            | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| 25–29.9              | 1.03 (1.00–1.05)       | 1.03 (1.00–1.05)                  | 1.04 (1.01–1.06)                                     |         |
| ≥ 35.0               | 1.06 (1.02–1.10)       | 1.06 (1.02–1.09)                  | 1.08 (1.04–1.11)                                     |         |
| Interaction test     | 1.14 (1.08–1.20)       | 1.13 (1.07–1.19)                  | 1.15 (1.09–1.21)                                     | 0.56    |
| **Perinatal mortality** |                      |                                   |                                                      |         |
| GDM                  | 1.05 (0.83–1.32)       | 0.90 (0.70–1.14)                  | 0.79 (0.62–1.01)                                     |         |
| No GDM               | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| BMI groups (kg/m²)   |                        |                                   |                                                      |         |
| < 18.5               | 0.90 (0.73–1.11)       | 0.90 (0.73–1.11)                  | 0.89 (0.72–1.09)                                     |         |
| 18.5–24.9            | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| 25–29.9              | 1.51 (1.42–1.61)       | 1.51 (1.42–1.61)                  | 1.49 (1.40–1.59)                                     |         |
| ≥ 35.0               | 2.04 (1.88–2.22)       | 2.04 (1.88–2.22)                  | 2.01 (1.85–2.19)                                     |         |
| Interaction test     | 2.87 (2.58–3.19)       | 2.88 (2.59–3.21)                  | 2.84 (2.55–3.17)                                     | 0.86    |
| **Stillbirth**       |                        |                                   |                                                      |         |
| GDM                  | 1.16 (0.90–1.51)       | 1.0 (0.77–1.31)                   | 0.87 (0.66–1.13)                                     |         |
| No GDM               | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| BMI groups (kg/m²)   |                        |                                   |                                                      |         |
| < 18.5               | 0.91 (0.71–1.15)       | 0.91 (0.71–1.15)                  | 0.90 (0.70–1.14)                                     |         |
| 18.5–24.9            | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| 25–29.9              | 1.53 (1.43–1.65)       | 1.53 (1.43–1.65)                  | 1.51 (1.40–1.62)                                     |         |
| ≥ 35.0               | 2.10 (1.91–2.32)       | 2.10 (1.91–2.32)                  | 2.06 (1.87–2.27)                                     |         |
| Interaction test     | 2.89 (2.56–3.27)       | 2.89 (2.56–3.27)                  | 2.85 (2.52–3.22)                                     | 0.38    |
| **Prematurity**      |                        |                                   |                                                      |         |
| GDM                  | 2.02 (1.91–2.14)       | 1.91 (1.80–2.03)                  | 1.87 (1.76–1.98)                                     |         |
| No GDM               | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| BMI groups (kg/m²)   |                        |                                   |                                                      |         |
| < 18.5               | 1.40 (1.34–1.47)       | 1.41 (1.34–1.47)                  | 1.37 (1.31–1.44)                                     |         |
| 18.5–24.9            | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| 25–29.9              | 1.07 (1.05–1.09)       | 1.06 (1.04–1.08)                  | 1.08 (1.06–1.10)                                     |         |
| ≥ 35.0               | 1.24 (1.20–1.28)       | 1.22 (1.18–1.25)                  | 1.24 (1.20–1.27)                                     |         |
| Interaction test     | 1.54 (1.48–1.60)       | 1.48 (1.42–1.54)                  | 1.49 (1.43–1.55)                                     | 0.30    |
| **Apgar < 4 at 5 min of age** |          |                                   |                                                      |         |
| GDM                  | 1.85 (1.51–2.26)       | 1.54 (1.24–1.91)                  | 1.36 (1.10–1.70)                                     |         |
| No GDM               | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| BMI groups (kg/m²)   |                        |                                   |                                                      |         |
| < 18.5               | 0.80 (0.62–1.02)       | 0.80 (0.62–1.02)                  | 0.78 (0.61–1.00)                                     |         |
| 18.5–24.9            | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| 25–29.9              | 1.44 (1.33–1.55)       | 1.44 (1.34–1.54)                  | 1.45 (1.35–1.56)                                     |         |
| ≥ 35.0               | 1.79 (1.62–1.97)       | 1.76 (1.60–1.95)                  | 1.80 (1.63–1.98)                                     |         |
| Interaction test     | 2.80 (2.49–3.15)       | 2.73 (2.42–3.08)                  | 2.81 (2.49–3.17)                                     | 0.38    |
| **Fetal distress**   |                        |                                   |                                                      |         |
| GDM                  | 1.20 (1.13–1.27)       | 1.15 (1.08–1.22)                  | 1.09 (1.02–1.16)                                     |         |
| No GDM               | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| BMI groups (kg/m²)   |                        |                                   |                                                      |         |
| < 18.5               | 0.97 (0.93–1.01)       | 0.97 (0.93–1.02)                  | 0.96 (0.92–1.01)                                     |         |
| 18.5–24.9            | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| 25–29.9              | 1.05 (1.04–1.07)       | 1.05 (1.04–1.07)                  | 1.14 (1.12–1.15)                                     |         |
| ≥ 35.0               | 1.14 (1.11–1.17)       | 1.14 (1.11–1.16)                  | 1.29 (1.26–1.32)                                     |         |
| Interaction test     | 1.23 (1.18–1.27)       | 1.22 (1.17–1.26)                  | 1.40 (1.35–1.46)                                     | 0.16    |
| **Erb’s palsy**      |                        |                                   |                                                      |         |
| GDM                  | 3.28 (2.64–4.08)       | 2.36 (1.87–2.98)                  | 2.26 (1.79–2.86)                                     |         |
| No GDM               | 1 (reference)          | 1 (reference)                     | 1 (reference)                                        |         |
| BMI groups (kg/m²)   |                        |                                   |                                                      |         |
stillbirth in women with GDM. Billionnet et al. [14] showed an increased risk for perinatal mortality for women with GDM after 37 weeks; however, they were not able to adjust for maternal BMI in their analyses. Feig et al. [24] reported decreased risks of perinatal mortality in women with GDM compared with pregnancies without diabetes. They argue that this might be due to more intense management in pregnancies of women with GDM. This is in contrast to the findings in our study, which is more in line with the results of Ovesen et al. [27]. The finding is interesting because women with GDM in this study were diagnosed using higher cut-off values for plasma glucose than the International Association of Diabetes in Pregnancy Study Group (IADPSG) criteria [28].

There are few studies reporting risks of fetal distress and low Apgar scores in offspring of pregnancies in women with GDM. Ovesen et al. [27] found no significant differences in Apgar score < 7 at 5 min in offspring of women with or without GDM. In the ACHOIS study, a randomized controlled trial of women with GDM receiving active treatment (dietary advice, blood glucose monitoring and insulin therapy) or routine care, there was no difference in risk of low Apgar score between the offspring of mothers in the routine care and the intervention groups [29]. In the current study, we used Apgar < 4 at 5 min because it is a strong predictor of neonatal complications [30]. We found a slightly elevated risk of low Apgar scores in offspring of women with GDM compared with women without GDM. Offspring of mothers with GDM also had a slightly elevated risk of fetal distress, and in offspring of mothers without GDM risks increased with maternal BMI. This is in contrast to the finding of a markedly increased risk of fetal distress in offspring of mothers with Type 1 diabetes [31].

The risk of Erb’s palsy has been studied previously with contradictory results. There are studies reporting no increased risks of Erb’s palsy in offspring of women with GDM [32,33]. In a previous Swedish study, the risk of Erb’s palsy was more than doubled in offspring of women with GDM, even after taking maternal BMI into account [34]. We confirm these results and also show that overweight/obesity had a similar impact on the relative risk of Erb’s palsy as GDM. Because we have shown that there was no interaction, the risks of Erb’s palsy associated with overweight/obesity are additional to the risk conveyed by GDM.

We also repeated all calculations including only women with a term pregnancy (> 37 weeks) because that is the vast majority of women seen in the clinics. This did not change the conclusions.

The rate of GDM in Sweden is low due to screening policies, strict diagnostic criteria and generally, a low background prevalence of Type 2 diabetes. Whether a more extensive GDM screening programme and a more stringent treatment regimen would reduce the risks of neonatal morbidity need to be further studied and explored. Further research is also needed into pre-pregnancy and antenatal interventions that will reduce the risk of adverse neonatal outcomes among overweight and obese women [35,36].

Improvements in uncommon, but serious outcomes such as stillbirth and perinatal mortality need research into interventions that both reduce the effects of hyperglycaemia and prevent/better manage overweight/obesity.

### Author contributions

The study was conceived by KH, HF and UH; planned by KH, HF and UH; performed by KH, HF and MP; analysed by KH, HF and AM; and written by KH, HF, MP, AM, DS and UH.

### Funding sources

Region Örebro County financed research time for KH, HF and DS.

### Competing interests

None declared.

### Acknowledgements

Örebro County Council has financed research time for KH and HF.
References

1 World Health Organization. Obesity and Overweight. Available at http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight Last accessed 30 April 2018.

2 Simmons D. Diabetes and obesity in pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25: 25–36.

3 Fadl HE, Simmons D. Trends in diabetes in pregnancy in Sweden 1998–2012. BMJ Open Diabetes Res Care 2016; 4: e000221.

4 Catalanio PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care 2012; 35: 780–786.

5 HAPO Study Cooperative Research Group. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. BJOG 2010; 117: 573–584.

6 Leng J, Shao P, Zhang C, Tian H, Zhang F, Zhang S et al. Prevalence of gestational diabetes mellitus and its risk factors in Chinese pregnant women: a prospective population-based study in Tianjin. China. PLoS One 2015; 10: e0121029.

7 Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 2009; 301: 636–650.

8 Chu SY, Kim SY, Lau J, Schmid CH, Dietz PM, Callaghan WM et al. Maternal obesity and risk of stillbirth: a metaanalysis. Am J Obstet Gynecol 2007; 197: 223–228.

9 Cnattingius S, Villamar S, Johansson S, Edstedt Bonamy AK, Persson M, Wikstrom AK et al. Maternal overweight and obesity and risks of severe birth-asphyxia-related complications in term infants: a population-based cohort study in Sweden. PLoS Med 2014; 11: e1001648.

10 Persson M, Johansson S, Villamar E, Cnattingius S. Maternal overweight and obesity and risks of severe birth-asphyxia-related complications in term infants: a population-based cohort study in Sweden. PLoS Med 2014; 11: e1001648.

11 Black MH, Sacks DA, Xiang AH, Lawrence JM. The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth. Diabetes Care 2013; 36: 56–62.

12 Scott-Pillai R, Spence D, Cardwell CR, Hunter A, Holmes VA. The impact of body mass index on maternal and neonatal outcomes: a retrospective study in a UK obstetric population, 2004–2011. BJOG 2013; 120: 932–939.

13 Hilden K, Hanson U, Persson M, Fadl H. Overweight and obesity: a remaining problem in women treated for severe gestational diabetes. Diabet Med 2016; 33: 1045–1051.

14 Billonnnet C, Mitanchez D, Weill A, Nizard J, Alla F, Hartemann A et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia 2017; 60: 636–644.

15 Parnell AS, Correa A, Reece EA. Pre-pregnancy obesity as a modifier of gestational diabetes and birth defects associations: a systematic review. Matern Child Health J 2017; 21: 1105–1120.

16 Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.

17 Socialstyrelsen. The Swedish Medical Birth Register. Available at https://www.socialstyrelsen.se/register/halsodataregister/medicinsk skafoedersregistret/menglish Last accessed 30 April 2018.

18 Graviditetsregistret. Arssrapport 2015. Available at https://www.medscinet.com/gr/uploads/hemsida/dokumentarkiv/Arssrapport_2015_Graviditetsregistret_14_webb.pdf Last accessed 30 April 2018.

19 Anderberg E, Kallen K, Berntorp K, Frid A, Aberg A. A simplified oral glucose tolerance test in pregnancy: compliance and results. Acta Obstet Gynecol Scand 2007; 86: 1432–1436.

20 World Health Organization. Guidelines Approved by the Guidelines Review Committee. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Geneva: WHO, 2013.

21 Persson M, Pasupathy D, Hanson U, Westgren M, Norman M. Pre-pregnancy body mass index and the risk of adverse outcome in type 1 diabetic pregnancies: a population-based cohort study. BJM Open 2012; 2: e000601.

22 Sheffield JS, Butler-Koster EL, Casey BM, McIntire DD, Leveno KJ. Maternal diabetes mellitus and infant malformations. Obstet Gynecol 2002; 100: 925–930.

23 Gabbay-Benszv R, Reece EA, Wang F, Yang P. Birth defects in pregestational diabetes: defect range, glycemic threshold and pathogenesis. World J Diabetes 2015; 6: 481–488.

24 Feig DS, Hwee J, Shah BR, Booth GL, Bierman AS, Lipscombe LL. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996–2010. Diabetes Care 2014; 37: 1590–1596.

25 Yao R, Ananth CV, Park BY, Pereira L, Plante LA. Obesity and the risk of stillbirth: a population-based cohort study. Am J Obstet Gynecol 2014; 210: 457. e451–459.

26 Vasudevan C, Renfrew M, McGuire W. Fetal and perinatal consequences of maternal obesity. Arch Dis Child Fetal Neonatal Ed 2011; 96: F378–F382.

27 Ovesen PG, Jensen DM, Damm P, Rasmussen S, Kesmodel U. Maternal and neonatal outcomes in pregnancies complicated by gestational diabetes, a nation-wide study. J Matern-Fetal Neonatal Med 2015; 28: 1720–1724.

28 Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalanio PM, Damm P et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676–682.

29 Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 2477–2486.

30 Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med 2001; 344: 467–471.

31 Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study. Diabetes Care 2009; 32: 2005–2009.

32 Okby R, Shieier E. Risk factors for neonatal brachial plexus paralysis. Arch Gynecol Obstet 2012; 286: 333–336.

33 Lindqvist PG, Ajne G, Cooray C, Ericsson K, Gudmundsson S, Dahlin LB. Identification of pregnancies at increased risk of brachial plexus birth palsy – the construction of a weighted risk score. J Matern-Fetal Neonatal Med 2014; 27: 252–256.

34 Fadl HE, Oslund IK, Magnuson AF, Hanson US. Maternal and neonatal outcomes and time trends of gestational diabetes mellitus in Sweden from 1991 to 2003. Diabet Med 2010; 27: 436–441.

35 Muktabhant B, Lawrie TA, Lumbiganon P, Laopaiboon M. Diet or exercise, or both, for preventing excessive weight gain in pregnancy. Cochrane Database Syst Rev 2015; (6)CD007145.

36 Opray N, Grivell RM, Deussen AR, Dodd JM. Directed preconception health programs and interventions for improving pregnancy outcomes for women who are overweight or obese. Cochrane Database Syst Rev 2015; (7)CD010932.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Odds ratios (95% CI) for maternal characteristics and perinatal outcomes in women with missing BMI compared with normal weight women.